Population kinetics of homoarginine and optimized supplementation for cardiovascular risk reduction.

Amino acids Cardiovascular disease Homoarginine Kinetic Pharmacometrics Population pharmacokinetics

Journal

Amino acids
ISSN: 1438-2199
Titre abrégé: Amino Acids
Pays: Austria
ID NLM: 9200312

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 22 12 2021
accepted: 01 05 2022
pubmed: 27 5 2022
medline: 24 6 2022
entrez: 26 5 2022
Statut: ppublish

Résumé

Homoarginine is an endogenous amino acid whose levels are reduced in patients with renal, cardio- and cerebrovascular disease. Moreover, low homoarginine concentrations independently predict morbidity and mortality in these patients. Besides endogenous synthesis, homoarginine is also a constituent of the human diet. The objective of the present study was to analyze the kinetics of orally supplemented homoarginine in human plasma by means of a pharmacometric approach. We developed a pharmacometric model to evaluate different dosing regimens, especially the regimen of 125 mg once weekly, based on a previous clinical study (n = 20). The model was adapted to account for differences in baseline homoarginine plasma concentrations between healthy and diseased individuals. A novel dosing regimen of 25 mg once daily led to higher attainment of homoarginine reference concentrations using clinical trial simulations. With 25 mg/day, the trough concentration of only 6% of the older and 3.8% of the younger population was predicted to be below the target concentration of 2.0-4.1 µmol/L. In synopsis, the new dosing regimen recapitulates the kinetics of homoarginine in healthy individuals optimally.

Identifiants

pubmed: 35618975
doi: 10.1007/s00726-022-03169-x
pii: 10.1007/s00726-022-03169-x
pmc: PMC9213336
doi:

Substances chimiques

Homoarginine 156-86-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

889-896

Informations de copyright

© 2022. The Author(s).

Références

Amino Acids. 2015 Sep;47(9):1921-9
pubmed: 26077714
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2294-8
pubmed: 21737361
Biochem J. 1962 Oct;85:91-3
pubmed: 13970459
Circulation. 2017 Feb 7;135(6):544-555
pubmed: 28153991
Circulation. 2013 Sep 24;128(13):1451-61
pubmed: 24004504
CPT Pharmacometrics Syst Pharmacol. 2014 Dec 22;3:e153
pubmed: 25531560
J Clin Neurosci. 2018 Apr;50:237-241
pubmed: 29396070
Amino Acids. 2015 Sep;47(9):1847-52
pubmed: 25655383
J Am Heart Assoc. 2016 Apr 13;5(4):e002565
pubmed: 27076564
FEBS Lett. 2012 Oct 19;586(20):3653-7
pubmed: 23010440
Sci Rep. 2017 Jul 6;7(1):4767
pubmed: 28684763
Int J Cardiol. 2016 Aug 15;217:12-5
pubmed: 27174592
Circ Cardiovasc Genet. 2013 Oct;6(5):505-13
pubmed: 24047826
Nature. 1962 Mar 17;193:1078-9
pubmed: 13866803
Ann Intern Med. 2003 Jul 15;139(2):137-47
pubmed: 12859163
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Nephron. 1976;16(1):31-41
pubmed: 1244564
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2501-7
pubmed: 25189571
PLoS One. 2019 Mar 13;14(3):e0213747
pubmed: 30865704
Biochemistry. 1963 Mar-Apr;2:298-300
pubmed: 13973060
Int J Cardiol. 2013 Oct 12;168(5):4907-9
pubmed: 23890923
Amino Acids. 2017 Jul;49(7):1193-1202
pubmed: 28429125
Clin Chem Lab Med. 2016 Jul 1;54(7):1231-7
pubmed: 26562034
Hum Mol Genet. 2013 Jan 1;22(1):110-23
pubmed: 23026748
Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485
pubmed: 27434056
PLoS One. 2013 Sep 04;8(9):e72694
pubmed: 24023762

Auteurs

Christine J Kleist (CJ)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Bundesstraße 45, 20146, Hamburg, Germany.

Chi-Un Choe (CU)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Dorothee Atzler (D)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-Universität, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität, Munich, Germany.
Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Mirjam Schönhoff (M)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Rainer Böger (R)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.

Edzard Schwedhelm (E)

Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.

Sebastian G Wicha (SG)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Bundesstraße 45, 20146, Hamburg, Germany. sebastian.wicha@uni-hamburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH